Cybin net loss widens to $47.8 million in FY27 Q1

• Cybin posted a net loss of $47.8 million for the quarter ended June 30, 2026, widening from $24.6 million a year earlier.
• Cash-based operating expenses rose to $37.5 million from $23.9 million, while operating cash outflow increased to $37.1 million from $29.5 million.
• Cash totaled $166.4 million at June 30, 2026.
• Higher spending was driven by continued advancement of the APPROACH, EMBRACE, and EXTEND HLP003 Phase 3 trials.
• Cybin reiterated expectations for HLP003 Phase 3 topline data in Q4 2026, with HLP004 study design targeted for completion by end-Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001833141-26-000058), on August 14, 2026, and is solely responsible for the information contained therein.